Novartis generics subsidiary Sandoz made history ahead of the weekend after getting approval in the US for Zarxio, the first biosimilar cleared by the FDA.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
